Of these, 143 patients (82 (57%) on TNFi monotherapy and 61 (43%) on combination therapy) provided post-vaccination PBMC samples for spike-specific CD4 and CD8 T cell responses 2–4 weeks after up to four SARS-CoV-2 vaccine doses or a breakthrough infection (Fig. 1). This evidence concerns the gene CD8A and infection.